Glecaprevir/pibrentasvir in patients with chronic HCV and recent drug use: An integrated analysis of 7 phase III studies.

Graham R Foster,Gregory J Dore,Stanley Wang,Jason Grebely,Kenneth E Sherman,Axel Baumgarten,Brian Conway,Daniel Jackson,Tarik Asselah,Michael Gschwantler,Krzysztof Tomasiewicz,Humberto Aguilar,Armen Asatryan,Yiran Hu,Federico J Mensa

Drug and Alcohol Dependence（2019）

引用 39|浏览25

暂无评分

摘要

•Glecaprevir/pibrentasvir (G/P) achieved high SVR12 rates (93%) in recent drug users with chronic HCV infection.•Treatment adherence and completion were high (≥96%) regardless of drug use status.•G/P was well-tolerated, irrespective of drug use status.

查看译文

关键词

Hepatitis C,ABT-493,ABT-530,Injection drug use,Opioid substitution therapy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要